Question:
Large number of patients in medical research centers receive the drug provides information about infrequent or rare adverse effects FDA will approve a new drug application if satisfactory
Author: LEIGHTON DWIGHT OBILLOSAnswer:
Phase III
0 / 5 Â (0 ratings)
1 answer(s) in total